Clinical Trials for Age-Related Macular Degeneration

Age-related macular degeneration (AMD) is the leading cause of irreversible visual loss in the United States. (National Society to Prevent Blindness 1980) The manifestations of AMD are broken down into two forms: dry and wet or exudative. The wet form accounts for ~ 10% - 20% of cases, and is responsible for ~ 80%-90% of vision loss. (Ferris et al. 1984)

There remains a significant unmet need for therapeutic options in AMD, and The Retina Group of Washington is contributing to the advancement of these new treatments by participating in federally approved research studies. For more information on the research studies currently recruiting, contact our clinical research department and make an appointment with one of our physicians for an evaluation.
Phase II/III Study of Preservative-Free Triamcinolone Acetonide with PDT for Wet AMD

Sponsor: NEI
Status: Open to Enrollment
Principal Investigator: Michael Osman, M.D.

Phase III Study of Intravitreal Injections with Triamcinolone Acetonide and Laser Photocoagulation for Diabetic Macular Edema

Sponsor: Diabetic Retinopathy Clinical Research Network
Status: Open to Enrollment
Principal Investigator: William Phillips, M.D.

Natural History Study - Idiopathic Macular Telangiectasis

Sponsor: The MacTel Foundation
Status: Open to Enrollment
Principal Investigator: Robert Murphy, M.D.

Phase II Study of Intravitreal Injections with Macugen vs Sham for CRVO (Central Retinal Vein Occlusion)

Sponsor: Eyetech Pharmaceuticals
Status: Closed to Enrollment
Principal Investigator: Richard Garfinkel, M.D.

Phase I/II Study of Sub-Tenon Injections with AG013958 for Wet AMD

Sponsor: Pfizer Inc.
Status: Closed to Enrollment
Principal Investigator: Daniel Berinstein, M.D.

Phase III Study of Intravitreal Injections with Ranibizumab vs Sham for Wet AMD

Sponsor: Genentech, Inc.
Status: Closed to Accrual
Principal Investigator: Reginald Sanders, M.D.

Phase II Study of Implantable Minaturized Telescope for Macular Degeneration or Stargard’s Macular Dystrophy

Sponsor: VisionCare Ophthalmics Technologies, Inc.
Status: Closed to Accrual
Principal Investigator: Daniel Berinstein, M.D.

Phase III Study of Ranibizumab Compared with PDT for Predominantly Classic Subfoveal Neovascular AMD

Sponsor: Genentech, Inc.
Status: Closed to Accrual
Principal Investigator: Daniel Berinstein, M.D.

Phase II Pilot Study of Laser Photocoagulation for Diabetic Macular Edema

Sponsor: Diabetic Retinopathy Clinical Research Network
Status: Closed to Accrual
Principal Investigator: William Phillips, M.D.

Fellowship Information Brochure
About Us | Our Doctors | Locations | Clinical Studies | Referring Doctors
Macular Degeneration | Incidence | Early Detection | Management | Info Links
Examination Services | Surgery Services | Contact Us - Times
Contact Us - Insurance Information
Patient Forms